Universal Health Services
UHS
$174.62
-1.39%
Universal Health Services, Inc. Class B operates acute care hospitals and behavioral health centers, primarily in the United States, with a smaller presence in the UK. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and numerous outpatient facilities, making it one of the largest hospital operators in the nation. Its business model is distinct in that behavioral health services, while contributing less than half of revenue, generate the majority of pretax profits due to higher margins, giving UHS a unique profitability profile among peers. The current investor narrative centers on UHS's strategic acquisition of Talkspace, a digital behavioral health platform, aimed at capturing the growing online therapy market, though near-term costs have raised caution. Additionally, the company's concentrated exposure to states like Nevada, Texas, and California exposes it to regional economic and regulatory dynamics, while its UK operations add an element of currency and geopolitical risk.…
UHS
Universal Health Services
$174.62
Related headlines
Investment Opinion: Should I buy UHS Today?
Based on the synthesis of data, UHS warrants a Hold rating with a value bias. The analyst consensus is Buy (mean 2.4) with an average target price of $194.35, implying 10.6% upside, but the stock's recent underperformance and margin pressures suggest limited near-term catalysts. The core thesis is that UHS is deeply undervalued (PE of 9.31 vs. industry 22.0) but faces earnings headwinds that may delay a re-rating. Supporting evidence includes: (1) revenue growth of 8.27% YoY in Q2 2026, (2) trailing PE of 9.31 and forward PE of 7.32, both well below the industry average, (3) free cash flow of $826.7 million TTM, and (4) a dividend yield of 0.37% with a low payout ratio of 3.44%, indicating room for growth. However, the operating margin decline to 11.14% and net margin of 7.73% are concerns. The biggest risks are margin compression, Talkspace integration challenges, and regional concentration. The rating would upgrade to Buy if operating margins stabilize above 12% and revenue growth accelerates above 10%, or downgrade to Sell if margins fall below 10% or revenue growth decelerates below 5%. Relative to its history (PE range 6.19-17.68) and peers (industry PE 22.0), UHS is undervalued, but the discount may persist until operational improvements materialize.
Sign up to view all
UHS 12-Month Price Forecast
UHS presents a mixed picture: deep value (PE 9.31) and consistent revenue growth (8.27% YoY) are offset by margin compression and integration risks from the Talkspace acquisition. The stock's recent momentum (+4.91% 1-month) suggests improving sentiment, but the 1-year underperformance (-14.51%) and high volatility (beta 1.061) warrant caution. The base case (55% probability) targets $180-210, implying modest upside, while the bear case (20%) could see a retest of $140. I would upgrade to bullish if operating margins stabilize above 12% and revenue growth accelerates above 10%; I would downgrade to bearish if margins fall below 10% or revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Universal Health Services's 12-month outlook, with a consensus price target around $194.94 and implied upside of +11.6% versus the current price.
Average Target
$194.94
0 analysts
Implied Upside
+11.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$166 - $290
Analyst target range
Seventeen analysts cover UHS, with a consensus recommendation of Buy (mean rating 2.4). The average target price is $194.35, implying a 10.6% upside from the current price of $175.72. The consensus leans bullish, with a majority of analysts recommending Buy or Outperform, though some maintain Neutral ratings. The target range spans from a low of $166 to a high of $290, reflecting a wide spread that indicates differing views on the company's prospects. The high target of $290 assumes successful integration of Talkspace, accelerating revenue growth, and multiple expansion, while the low target of $166 implies stagnation or margin compression. Recent institutional ratings show a mix of Neutral and Buy ratings, with no significant upgrades or downgrades, suggesting stable sentiment. The wide target spread signals uncertainty, but the average target still offers upside potential.
Bulls vs Bears: UHS Investment Factors
The bear case currently has stronger evidence, given UHS's significant underperformance (-14.51% 1-year return vs. S&P 500's +15.01%), margin compression, and high volatility. However, the bull case is gaining traction with recent momentum (+4.91% 1-month) and deep value metrics (PE of 9.31 vs. industry 22.0). The most important tension is whether UHS can reverse its margin decline and successfully integrate Talkspace to drive earnings growth, which would justify a re-rating from its historically low valuation. If margin pressures persist, the stock could remain undervalued for a prolonged period.
Bullish
- Deep Value on Earnings: UHS trades at a trailing PE of 9.31 and forward PE of 7.32, a 57.7% discount to the industry average PE of 22.0. The forward PE implies the market expects earnings growth, and the PEG ratio of 0.255 suggests the stock is significantly undervalued relative to its growth rate.
- Consistent Revenue Growth: Q2 2026 revenue grew 8.27% YoY to $4.638 billion, continuing a multi-quarter trend with Q1 2026 at $4.495 billion and Q4 2025 at $4.486 billion. This steady top-line momentum supports the investment case.
- Strong Cash Generation: UHS generated $826.7 million in trailing twelve-month free cash flow, providing ample internal funding for growth initiatives and shareholder returns. The interest coverage ratio of 12.95x EBIT demonstrates strong debt-servicing capacity.
- Analyst Consensus Upside: Seventeen analysts cover UHS with a consensus Buy rating (mean 2.4) and an average target price of $194.35, implying 10.6% upside from the current price of $175.72. The high target of $290 suggests significant potential if integration succeeds.
Bearish
- Significant Underperformance: UHS is down 14.51% over the past year, vastly underperforming the S&P 500's +15.01% gain. The YTD decline of 20.08% and relative strength of -32.94% YTD highlight persistent weakness and loss of investor confidence.
- Margin Compression: Operating margin declined to 11.14% in Q2 2026 from 11.68% in Q2 2025, and net margin fell to 7.73% from 8.25% YoY. Rising labor costs and Talkspace integration expenses are pressuring profitability.
- High Volatility and Drawdown: The stock has a beta of 1.061 and experienced a max drawdown of -42.19% over the past year. The 52-week range of $140.08 to $246.33 shows extreme price swings, with the current price 33.6% above the low but 28.7% below the high.
- Talkspace Integration Risks: The acquisition of Talkspace, approved by shareholders in May 2026, aims to capture the online therapy market but has raised caution about near-term costs. Integration challenges could further pressure margins and distract management.
UHS Technical Analysis
UHS is in a recovery phase after a significant downtrend, with the stock currently trading at $175.72, down 14.51% over the past year. The current price sits at approximately 33.6% of its 52-week range (low of $140.08, high of $246.33), indicating that while it has rebounded from lows, it remains far below its peak, suggesting potential value but also lingering bearish sentiment. The 1-year change of -14.51% contrasts with the S&P 500's +15.01% gain, highlighting substantial underperformance. Over the past month, UHS has gained 4.91%, outpacing the S&P 500's 0.59% increase, signaling improving short-term momentum. The 3-month change of +10.98% further confirms this positive trend, diverging from the negative 1-year performance and potentially indicating a trend reversal. The 6-month change of -0.55% shows a slight decline, but the recent strength suggests a possible bottoming pattern. The relative strength versus the S&P 500 over 1 month is +4.32%, reflecting recent outperformance. Key technical levels include support at the 52-week low of $140.08, which if broken could trigger further downside, and resistance at the 52-week high of $246.33, a breakout above which would signal a strong bullish reversal. The beta of 1.061 indicates the stock is slightly more volatile than the market, implying that position sizing should account for this modest additional risk. The max drawdown of -42.19% over the past year underscores the significant downside risk that has been realized, but the recent recovery suggests improving sentiment.
Beta
1.03
1.03x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$140-$246
Price range past year
Annual Return
-16.7%
Cumulative gain past year
| Period | UHS Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | +0.9% |
| 3m | +12.5% | +3.4% |
| 6m | -3.4% | +14.4% |
| 1y | -16.7% | +16.2% |
| ytd | -20.6% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UHS Fundamental Analysis
UHS reported Q2 2026 revenue of $4.638 billion, representing an 8.27% year-over-year increase from $4.284 billion in Q2 2025. This growth continues a multi-quarter trend of steady revenue expansion, with Q1 2026 revenue at $4.495 billion and Q4 2025 at $4.486 billion, indicating consistent top-line momentum. The revenue mix shows acute care services contributing $2.610 billion and behavioral health services $1.882 billion, with both segments likely benefiting from increased patient volumes and favorable reimbursement rates. The consistent growth trajectory supports a positive investment case, though the pace of growth is moderate. The company is profitable, with Q2 2026 net income of $358.4 million and a net margin of 7.73%, up from 8.25% in Q2 2025. Gross margin remains robust at 90.87%, though this is typical for healthcare providers due to the nature of cost of revenue. Operating margin stood at 11.14%, slightly lower than the 11.68% in Q2 2025, indicating some margin compression, possibly due to rising labor costs or integration expenses from the Talkspace acquisition. The net margin improvement year-over-year suggests effective cost management despite these pressures. UHS maintains a debt-to-equity ratio of 0.757, which is moderate for the healthcare sector, and a current ratio of 1.052, indicating adequate short-term liquidity. The company generated $826.7 million in trailing twelve-month free cash flow, providing ample internal funding for growth initiatives and shareholder returns. Return on equity is a healthy 20.46%, reflecting efficient use of shareholder capital. The interest coverage ratio of 12.95 times EBIT demonstrates a strong ability to service debt, and the cash flow to debt ratio of 0.084 suggests manageable leverage. Overall, UHS's financial health is solid, with sufficient cash generation to support its strategic investments without relying heavily on external financing.
Quarterly Revenue
$4.6B
2026-06
Revenue YoY Growth
+8.3%
YoY Comparison
Gross Margin
90.9%
Latest Quarter
Free Cash Flow
$826724000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UHS Overvalued?
Since UHS reported positive net income, the trailing PE ratio is the primary valuation metric. The trailing PE is 9.31, while the forward PE is 7.32, indicating that the market expects earnings growth in the coming year. The gap between trailing and forward PE suggests that analysts anticipate improved profitability, likely driven by revenue growth and margin expansion. Compared to the industry average PE of 22.0 for Medical Care Facilities, UHS trades at a significant discount, with a PE of 9.31 representing a 57.7% discount. This discount may be justified by the company's lower growth rate relative to some peers, but it could also present a value opportunity if UHS can sustain its recent momentum. The price-to-sales ratio of 0.798 is also below the industry average of 1.5, further indicating undervaluation. Historically, UHS's PE ratio has ranged from 6.19 to 17.68 over the past five years, with the current 9.31 near the lower end of that range. This suggests that the stock is trading at a valuation that is historically attractive, potentially pricing in pessimistic expectations. However, the low valuation could also reflect concerns about regulatory pressures, integration risks from the Talkspace acquisition, or broader industry headwinds.
PE
9.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~18x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. UHS carries a debt-to-equity ratio of 0.757, which is manageable but not insignificant, and a current ratio of 1.052 indicates tight short-term liquidity. The company's operating margin has compressed to 11.14% from 11.68% YoY, and net margin fell to 7.73% from 8.25%, driven by rising labor costs and Talkspace integration expenses. Revenue is concentrated in acute care (56% of Q2 2026 revenue) and behavioral health (44%), with the latter generating over 55% of pretax profits, so any slowdown in behavioral health volumes or reimbursement rates could disproportionately impact profitability. Additionally, the company's free cash flow of $826.7 million TTM provides a cushion, but continued margin erosion could limit internal funding for growth. Market and competitive risks include valuation compression if UHS fails to meet growth expectations, given its premium historical PE range of 6.19 to 17.68 and current PE of 9.31 near the low end. The stock's beta of 1.061 means it is slightly more volatile than the market, and sector rotation away from healthcare could exacerbate declines. Regulatory headwinds, such as potential changes to Medicaid/Medicare reimbursement or drug pricing policies (e.g., Trump administration's proposed 100% tariffs on drugmakers), could pressure margins. Competitive threats from other hospital operators and digital health entrants, like Teladoc, could erode UHS's market share in behavioral health. The recent Talkspace acquisition, while strategic, faces integration risks and competition from established telehealth providers. Worst-case scenario: a combination of margin compression, failed Talkspace integration, and regulatory pressures could drive the stock down to its 52-week low of $140.08, representing a 20.3% decline from the current price of $175.72. If the bear case target of $166 is breached and negative sentiment persists, the stock could test the 52-week low, implying a loss of approximately 20% from current levels. A more severe scenario, such as a recession reducing patient volumes and reimbursement cuts, could push the stock below $140, but that would require a significant deterioration in fundamentals. The max drawdown of -42.19% over the past year illustrates the potential for substantial losses in adverse conditions.
FAQ
The key risks include: (1) Financial risk: operating margin compression to 11.14% from 11.68% YoY, with net margin at 7.73%, and a debt-to-equity ratio of 0.757. (2) Integration risk: the Talkspace acquisition may not deliver expected synergies, adding near-term costs and distracting management. (3) Regulatory risk: changes to Medicaid/Medicare reimbursement or drug pricing policies could pressure margins. (4) Concentration risk: 21% of operating profits come from Nevada, 19% from Texas, and 13% from California, exposing the company to regional economic downturns. (5) Market risk: the stock has a beta of 1.061 and a max drawdown of -42.19% over the past year, indicating high volatility. These risks are ranked from highest to lowest severity, with margin compression and integration risk being the most immediate.
The 12-month forecast has three scenarios: Bull case (25% probability) targets $246.33-$290, assuming successful Talkspace integration and margin recovery above 12%. Base case (55% probability) targets $180-$210, assuming steady 7-8% revenue growth and stable margins. Bear case (20% probability) targets $140.08-$166, assuming margin compression below 10% and integration failures. The most likely scenario is the base case, with a target around the analyst average of $194.35, implying 10.6% upside. The key assumption is that operating margins stabilize and revenue growth remains in the high single digits. However, the wide analyst target range ($166-$290) reflects significant uncertainty.
UHS appears undervalued on multiple metrics. Its trailing PE of 9.31 is well below the industry average of 22.0, and its forward PE of 7.32 suggests the market expects earnings growth. The price-to-sales ratio of 0.798 is also below the industry average of 1.5. Historically, UHS's PE has ranged from 6.19 to 17.68, and the current 9.31 is near the lower end, indicating a discount to its own history. However, the low valuation may reflect legitimate concerns about margin pressures, regulatory risks, and integration challenges from the Talkspace acquisition. The market is pricing in pessimistic expectations, and a re-rating could occur if the company demonstrates sustained margin improvement and revenue acceleration.
UHS is a good buy for value investors with a long-term horizon, given its trailing PE of 9.31 (57.7% discount to the industry average of 22.0) and analyst average target of $194.35 (10.6% upside). However, the stock faces near-term headwinds, including a 14.51% 1-year decline and margin compression (operating margin down to 11.14% from 11.68%). The risk/reward is balanced: upside to the analyst high target of $290 is substantial, but downside to the 52-week low of $140.08 represents a 20.3% loss. It is most suitable for investors who can tolerate volatility and believe in the long-term value of behavioral health services and the Talkspace acquisition.
UHS is more suitable for long-term investment (minimum 2-3 years) given its value characteristics, steady revenue growth, and strategic initiatives like the Talkspace acquisition that may take time to materialize. The stock's beta of 1.061 and max drawdown of -42.19% indicate high volatility, making it less ideal for short-term trading unless one can actively manage risk. The dividend yield of 0.37% is low, so income is not a primary reason to hold. Earnings visibility is moderate, with consistent revenue growth but margin uncertainty. A long-term investor could benefit from a potential re-rating if margins improve and the digital health strategy succeeds, but patience is required.